Filtered By:
Source: Cardiovascular Therapeutics
Management: Medicare

This page shows you your search results in order of date.

Order by Relevance | Date

Total 2 results found since Jan 2013.

Clinical and Economic Outcomes among Elderly Myocardial Infarction Survivors in the United States
ConclusionsRisks of mortality and cardiovascular events remain high in a Medicare population surviving >1 year after a MI. Continuing healthcare costs are doubled over pre‐MI levels up to five years after an MI. Secondary prevention measures beyond the acute post‐MI period may be indicated to reduce risk and cost in this chronic disease phase.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - July 31, 2016 Category: Cardiology Authors: Erru Yang, Michael Stokes, Saga Johansson, Carl Mellstr öm, Elizabeth Magnuson, David J. Cohen, Phillip Hunt Tags: Original Research Article Source Type: research

Contraindications to Anticoagulation Therapy and Eligibility for Novel Anticoagulants in Older Patients With Atrial Fibrillation
ConclusionsOlder adults with atrial fibrillation rarely have absolute contraindications to oral anticoagulation therapy. Among patients without contraindications, most appeared to be eligible for any anticoagulant, and relatively high‐risk features appeared not to influence warfarin use.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - April 1, 2015 Category: Cardiology Authors: Benjamin A. Steinberg, Melissa A. Greiner, Bradley G. Hammill, Lesley H. Curtis, Emelia J. Benjamin, Susan R. Heckbert, Jonathan P. Piccini Tags: Original Research Article Source Type: research